Decoy Therapeutics Inc DCOY
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
The Small Cap Showcase Highlights 8 Public Companies at Their Investor Conference Today
-
Decoy Therapeutics to Present at The Small Cap Showcase
-
Decoy Therapeutics Reports Preclinical Data Supporting Once-Weekly Intranasal Dosing for DCOY-CoV Program
-
/C O R R E C T I O N — Decoy Therapeutics, Inc/
-
Decoy Therapeutics, Inc. Announces a Warrant Inducement Transaction for $3.85 Million in Gross Proceeds Priced At-The-Market under Nasdaq Rules
-
Decoy Therapeutics Expands Intellectual Property Portfolio Covering Designable Multi-Antivirals and the IMP³ACT™ Platform
-
Decoy Therapeutics Announces Breakthrough In Vitro Activity Against Ebola Zaire, Expanding D-MAV™ Platform into High Consequence Global Health Threats
Trading Information
- Previous Close Price
- $1.14
- Day Range
- $1.04–1.16
- 52-Week Range
- $1.04–49.56
- Bid/Ask
- $1.04 / $1.05
- Shares Outstanding
- 2.39M
- Market Cap
- $701,047.95
- Volume/Avg
- 76,073 / 2M
Key Statistics
- Price/Earnings (Normalized)
- 0.07
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Decoy Therapeutics Inc is a pre-clinical stage biotechnology company focused on advancing its pipeline of peptide conjugate therapeutics engineered through its proprietary IMP3ACT platform. The IMP3ACT platform represents a paradigm shift in peptide conjugate drug discovery and manufacturing, leveraging machine learning (ML) and artificial intelligence (AI" tools alongside high-speed synthesis techniques to rapidly engineer, optimize and manufacture peptide conjugates that target serious unmet medical needs. The company manages its business in one operating segment, focused on the discovery and development therapeutics for patients with high, unmet medical needs. Its pipeline programs include: Pan-Coronavirus; and Tripledemic.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 11
- Website
- https://www.decoytx.com
Valuation
|
Metric
|
DCOY
|
|---|---|
Price/Earnings (Normalized) | 0.07 |
Price/Book Value | 0.13 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
DCOY
Financial Strength
|
Metric
|
DCOY
|
|---|---|
Quick Ratio | 1.77 |
Current Ratio | 1.83 |
Interest Coverage | — |
Quick Ratio
DCOY
Profitability
|
Metric
|
DCOY
|
|---|---|
Return on Assets (Normalized) | −192.77% |
Return on Equity (Normalized) | −396.10% |
Return on Invested Capital (Normalized) | −400.88% |
Return on Assets
DCOY
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|^gP#B<X | LOCK|p$YV& | $133B | |||
| Moderna Inc
MRNA
| LOCK|t<BQ!# | LOCK|Dtw | $98B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|MxGL@^S | LOCK|Hc%@ | $83B | |||
| argenx SE ADR
ARGX
| LOCK|ymWGZh | LOCK|#n | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|^ND&TB | LOCK|&LD | $45B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|^g%S$B | LOCK|Vr&# | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|pSC<&hyy | LOCK|Fc#PV | $28B | |||
| Incyte Corp
INCY
| LOCK|vXsV<^ | LOCK|#z | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|ggbCD& | LOCK|g# | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|<$dhd@& | LOCK|QG | $14B |
United States